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Abstract: Colorectal cancer is the second most common cause of cancer related deaths in the 
United States. Recent developments have led to prolonged survival with the use of sequential 
lines of chemotherapy agents. The addition of bevacizumab to active chemotherapy has further 
improved survival when used in the ﬁ  rst and second lines of therapy for metastatic colorectal 
cancer. Evidence supporting the continued use of bevacizumab throughout lines of therapy 
is accumulating. Clinical trials are underway in which bevacizumab is continued beyond the 
ﬁ  rst line of a chemotherapy and bevacizumab combination regimen. The mechanism by which 
colorectal cancer may become resistant to bevacizumab is poorly understood. Molecular and 
biochemical correlates which may identify bevacizumab resistance are an important component 
in the design of these clinical trials.
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In the United States population, colorectal cancer (CRC) is the fourth most common 
cause of cancer and the second most common cause of cancer deaths. In 2007, there 
are expected to be 153,760 cases of CRC diagnosed, leading to 52,180 deaths (Jemal 
et al 2007). At the time of presentation, approximately 39% of patients will have local-
ized disease, 37% will have regional disease and 19% will have distant disease; with 
5-year relative survival rates of 90%, 68% and 10%, respectively. Both the incidence 
and death rate for CRC has been decreasing over the past 1–2 decades. This decrease 
can be attributed to improved screening strategies and more active therapy in the 
adjuvant and advanced disease setting. With current therapy, median overall survival 
(OS) for patients with advanced CRC approaches two years. Chemotherapy drugs with 
proven activity in CRC are 5-ﬂ  uorouracil (5FU), irinotecan (IRI) and oxaliplatin (OX). 
Monoclonal antibodies targeting the vascular endothelial growth factor (VEGF) and 
the epidermal growth factor receptor (EGFR) have added to the response rates (RR) 
and the OS that CRC patients now experience. Chemotherapy may be given as single 
agents or in combination, with sequential lines of therapy providing improved quality 
of life, tumor control, and prolonged survival. Enhancing the RR may lead to increasing 
the number of patients able to undergo potentially curative surgical resection.
Bevacizumab
Angiogenesis is a required component for normal development as well as tumor growth 
and metastases. It is a complex multistep process regulated by the balance of endog-
enous stimulatory and inhibitory factors to maintain equilibrium between vascular 
growth and cellular demands. During tumorigenesis, solid tumors ﬁ  rst undergo an 
avascular phase of growth until the diffusion of oxygen and the exchange of waste and 
nutrients become rate limiting. In response to the hypoxic microenvironment, genes 
which promote angiogenesis are upregulated (Jubb et al 2004). VEGF-A encodes a Biologics: Targets & Therapy 2008:2(1) 54
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proangiogenic ligand which binds tyrosine kinase receptors 
on angioblasts and endothelial cells activating the signal 
transduction cascade resulting in angiogenesis (Ferrara 
and Davis-Smyth 1997). The expression of VEGF-A is 
upregulated in a wide range of human tumors and has been 
associated with a worse prognosis and an increased incidence 
of disease recurrence (Ellis et al 2000). The vessels formed 
in the process of tumorigenesis are structurally and function-
ally abnormal (Jain 1994). An excess of endothelial cells and 
abnormal perivascular cells contribute to the formation of 
tortuous, dilated, and saccular blood vessels that are poorly 
organized and hyperpermeable. The physiologic results 
are a vascular network that is spatially and temporally 
heterogeneous, and unable to maintain a gradient between 
the vascular and interstitial pressures, leading to interstitial 
hypertension.
Bevacizumab (Avastin®; Genentech, Inc., South San 
Francisco, CA) is a recombinant humanized monoclonal 
antibody directed against VEGF-A. Preclinical studies 
demonstrated growth inhibition of human tumor xenografts 
in response to treatment with VEGF monoclonal antibody 
(Kim et al 1993). Subsequent clinical trials have established 
efﬁ  cacy of bevacizumab in various tumor types, with a 
survival beneﬁ  t in the treatment of CRC when combined 
with chemotherapy. The mechanism of action reﬂ  ects a 
restored balance of pro- and anti-angiogenic processes. 
VEGF inhibition prevents neovascularization and remodels 
existing vasculature through apoptosis of endothelial cells 
leading to a decrease in vessel diameter, density and per-
meability (Jain, 2005). The resultant decrease in interstitial 
hypertension and normalization of blood vessel structure 
promotes more efﬁ  cient delivery of oxygen and therapeutics 
into the tumor.
Markers demonstrating bevacizumab activity are lacking. 
Potential biomarkers to predict response to therapy have been 
explored. Response to therapy has not been associated with 
mutations in k-ras, b-raf, or p-53 (Ince et al 2005), nor with 
expression of VEFG-A, thrombospondin-2 or microvessel 
density (Jubb et al 2006). Phenotypic changes associated 
with angiogenesis inhibition include changes in vessel struc-
ture, vascular permeability, partial pressure of oxygen and 
interstitial pressure. These changes are not easily identiﬁ  ed 
and surrogate markers have been proposed. A phase I study 
treated six subjects with rectal cancer with bevacizumab, 
chemotherapy and radiation (Willett et al 2004). In response 
to bevacizumab alone, changes in tumor physiology were 
identiﬁ  ed as a decrease in interstitial ﬂ  uid pressure and, using 
functional computed tomography, a decrease in tumor blood 
perfusion and volume. With improved chemotherapeutic 
regimens for CRC, the addition of bevacizumab has further 
enhanced RR, progression-free survival (PFS), and OS.
First- and second-line 
chemotherapy
The ﬁ  rst line of chemotherapy for metastatic CRC is the 
combination of 5FU, modulated by leucovorin (LV) with 
IRI (IFL or FOLFIRI) or OX (FOLFOX) for patients with 
a good performance status. Single agent 5FU, either intra-
venous or as the oral agent capecitabine, for patients with a 
compromised performance status is acceptable. This ﬁ  rst line 
of chemotherapy is discontinued when 1) there is evidence 
of resistance as illustrated by disease progression, 2) there is 
intolerable cumulative toxicity, or 3) when stable disease is 
achieved and no further beneﬁ  t of therapy is evident. When 
evaluating the beneﬁ  t of second-line therapy, it is important 
to distinguish the reason for the discontinuation of the ﬁ  rst-
line therapy. Metastatic CRC that has demonstrated resistance 
to ﬁ  rst-line therapy may differ biologically from metastatic 
CRC that was responding or stable on ﬁ  rst-line therapy.
A beneﬁ  t of second-line therapy was ﬁ  rst illustrated in 
a pair of studies comparing IRI with infusion 5FU (Rougier 
et al 1998) and best supportive care (Cunningham et al 
1998) after progression on bolus 5FU. A series of phase II 
studies performed by Groupe d’Etude ET de Recherche en 
Cancreologie Onco-Radiotherapic (GERCOR) demonstrated 
a beneﬁ  t of OX when added to 5FU and LV after progression 
on 5FU and LV (Maindrault-Goebel et al 2000; Maindrault-
Goebel et al 2001). Subsequent studies demonstrated a 
beneﬁ  t of combination chemotherapy with either IFL (com-
pared to 5FU/LV and single agent IRI) (Saltz et al 2000), 
FOLFOX (compared to LV5FU2) (de Gramont et al 2000) 
or FOLFIRI (compared to 5FU/LV) (Douillard et al 2000) as 
ﬁ  rst-line therapy. Active second-line therapy with FOLFOX 
was demonstrated after progression on IFL (Rothenberg et al 
2003). Further deﬁ  ning the optimal ﬁ  rst-line therapy was 
attempted by the North Central Cancer Treatment Group 
(comparing IFL with IROX and FOLFOX) (Goldberg et al 
2004), and the Gruppo Oncologico Dell’Italia Meridionale 
(comparing FOLFIRI with FOLFOX) (Colucci et al 2005), 
among others. While it is clear that infusion schedules of 5FU 
are better tolerated than bolus schedules, no clear survival 
beneﬁ  t to any ﬁ  rst-line regimen emerged as long as all three 
active drugs are subsequently used (Grothey et al 2004). No 
optimal sequence was evident in the phase III study compar-
ing FOLFOX followed by FOLIRI or the inverse sequence 
(Tournigand et al 2004). In all of these studies, second-line Biologics: Targets & Therapy 2008:2(1) 55
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therapy was deﬁ  ned as therapy used after disease progression 
on ﬁ  rst-line therapy, demonstrating resistance to therapy.
The treatment of metastatic CRC has historically relied on 
continuous therapy until disease progression. The cumulative 
neurotoxicity associated with OX often requires patients 
to stop while still responding to therapy. This approach 
confounds the deﬁ  nition of second-line therapy. A stop-and-
go strategy was evaluated by the GERCOR in the Optimized 
5FU-Oxaliplatin study (OPTIMOX-1) (Tournigand et al 
2006). Chemotherapy naïve patients with metastatic CRC 
were randomly assigned to either FOLFOX-4 administered 
every 2 weeks until progressive disease or FOLFOX-7 
administered every 2 weeks for 6 cycles, then maintenance 
therapy without oxaliplatin (LV5FU2) for 12 cycles fol-
lowed by reintroduction of FOLFOX-7. With 620 subjects 
enrolled, the RR (58.5% and 59.2%, respectively), median 
PFS (9.0 and 8.7 months, respectively) and OS (19.3 and 
21.2 months, respectively) were not signiﬁ  cantly different in 
the two groups. The incidence of National Cancer Institute 
Common Toxicity Criteria (NCI CTC) grade 3 and 4 toxicity 
was greater for those on continuous oxaliplatin therapy com-
pared to those that stopped after 6 cycles (54.4% compared 
to 48.7%, respectively) and speciﬁ  cally grade 3 sensory 
neurotoxicity (17.9% and 13.3%). This stop-and-go strategy 
was further evaluated in the OPTIMOX-2 study in which sub-
jects were randomized to 6 cycles of FOLFOX-7 followed by 
LV5FU2 until progression and reintroduction of FOLFOX-7 
(OPTIMOX-1 strategy), or 6 cycles of FOLFOX-7, complete 
stop of chemotherapy and reintroduction of FOLFOX-7 
before the tumor progression reached the baseline mea-
surements (OPTIMOX-2 strategy) (Maindrault-Goebel 
et al 2007). Originally designed as a phase III study, it was 
re-designed as a phase II study after accrual suffered due to 
the demonstrated beneﬁ  t and availability of bevacizumab. 
With 202 subjects reported, the median overall survival was 
24.6 months in the OPTIMOX-1 arm and 18.9 months in the 
OPTIMOX-2 arm (p = 0.05). Those on the OPTIMOX-2 arm 
had a median chemotherapy free interval of 4 months. Based 
on these ﬁ  ndings, a complete chemotherapy free interval 
could not be recommended.
Bevacizumab in ﬁ  rst-line therapy
The addition of bevacizumab to the ﬁ  rst-line chemotherapy 
regimen has demonstrated an improvement in outcome 
parameters. In the pivotal study AVF2107 g, a statistically 
signiﬁ  cant survival beneﬁ  t was observed when bevacizumab 
was added to the IFL chemotherapy combination (median 
OS of 20.3 months compared to 15.6 months, p   0.001) 
(Hurwitz et al 2004). The addition of bevacizumab to 5FU 
and leucovorin was evaluated in a phase II study, AVF2192 g, 
for patients thought unﬁ  t for IFL (eg, advanced age, compro-
mised performance status, low serum albumin or prior pelvic 
radiation) (Kabbinavar et al 2005b). The PFS was found to be 
67% improved with the addition of bevacizumab (5.5 vs 9.2 
months; p = 0.0002). A pooled analysis of 249 subjects treated 
with 5FU, LV and bevacizumab from randomized studies fur-
ther supports the beneﬁ  t of this combination (median OS for 
chemotherapy alone and in combination with bevacizumab 
were 14.6 and 17.9 months, p = 0.0081) (Kabbinavar et al 
2005a). The preliminary results of NO16966 (Cassidy et al 
2007; Saltz et al 2007) comparing the infusion schedule of 
5FU and oxaliplatin (FOLFOX) with the oral schedule using 
capecitabine (XelOx) and a subsequent randomization to 
bevacizumab or placebo demonstrated superiority with the 
addition of bevacizumab (median PFS in the chemotherapy 
plus bevacizumab group 9.4 months compared to 8.0 months 
in the chemotherapy-alone group, HR = 0.83, p = 0.0023). 
This 1.4 month actual beneﬁ  t is less than has been seen in 
prior ﬁ  rst-line studies and has been attributed to the PFS 
deﬁ  nition used. Due to changing practice patterns, cumulative 
chemotherapy toxicities and ongoing studies demonstrating 
the safety of chemotherapy-free intervals, approximately 3 
times as many patients discontinued therapy prior to pro-
gression and unrelated to bevacizumab related toxicity in 
NO16966 than in AVF2107 g.
The OPTIMOX stop-and-go approach including bevaci-
zumab is being pursued in 2 phase III studies. The Spanish 
Cooperative Group for Gastrointestinal Tumour Therapy is 
comparing the time to disease progression of combination 
therapy with capecitabine, oxaliplatin and bevacizumab until 
disease progression or for 6 cycles followed by bevacizumab 
alone until disease progression or a premature drop out of 
the study (Spanish Cooperative Group for Gastrointestinal 
Tumor Therapy. Study of bevacizumab alone or combined 
with capecitabine and oxaliplatin as support therapy in meta-
static colorectal cancer patients. (Clinical Trials.gov. URL:
http://clinicaltrials.gov/ct/show/NCT00335595). A second 
trial, the DREAM (Double inhibition, Reintroduction, Erlo-
tinib, Avastin, Metastatic CRC) study is also a phase III trial 
in which patients receive a regimen of oxaliplatin with either 
infusion 5FU or capecitabine with bevacizumab (Groupe 
Cooperateur Multidsciplinaire en Oncologie (GERCOR). 
Combination chemotherapy and bevacizumab with or without 
erlotinib in treating patients with metastatic colorectal cancer 
that cannot be removed by surgery. (URL: http://clinicaltrials.
gov/ct/show/NCT00265824). Chemotherapy in all groups Biologics: Targets & Therapy 2008:2(1) 56
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is stopped after 6 cycles and patients are then randomized 
to receive either bevacizumab alone or bevacizumab with 
erlotinib during the chemotherapy-free interval.
Bevacizumab in refractory disease 
when bevacizumab naïve
The Eastern Cooperative Oncology Group (ECOG) study 3200 
evaluated bevacizumab in second-line therapy for patients 
that had progressed on therapy with 5FU and IRI (Giantonio 
et al 2007). The dose of bevacizumab used in this combina-
tion was 10 mg/kg every 2 weeks, as opposed to 5 mg/kg 
every 2 weeks as used in the ﬁ  rst-line studies. A randomized 
phase II study in metastatic CRC suggested that a dose of 5 
mg/kg was more effective than 10 mg/kg; however, the study 
was not powered to directly compare doses. The choice of 
this dose was made based on clinical and preclinical data 
demonstrating a dose-response effect (Manley et al 2002; 
Yang et al 2003). A total of 829 subjects were randomized 
to a regimen of FOLFOX-4, FOLFOX-4 with bevacizumab 
or bevacizumab alone after documented progression on 5FU 
and IRI. The primary endpoint was OS with a 95% power to 
detect a difference of 50%. The single agent bevacizumab arm 
was closed to accrual after a planned interim analysis sug-
gested an inferior survival compared to the two chemotherapy 
containing arms. With a median follow up of 28 months, the 
median OS for FOLFOX-4 with bevacizumab, FOLFOX-4, 
and bevacizumab alone was 12.9, 10.8, and 10.2 months, 
respectively with a hazard ratio of 0.75 (p = 0.0011) for the 
chemotherapy containing arms. The median PFS demonstrated 
a beneﬁ  t for the FOLFOX-4 with bevacizumab arm com-
pared to the FOLFOX-4 arm (7.3 compared to 4.7 months, 
hazard ratio for progression = 0.61; p   .0001). The median 
duration of therapy was 10 cycles for those treated with the 
FOLFOX-4 and bevacizumab, 7 for those with FOLFOX-4, 
and 4 for those with bevacizumab alone. The toxicity proﬁ  le 
reﬂ  ects the longer duration of therapy for the FOLFOX-4 with 
bevacizumab regimen. There were higher rates of NCI CTC 
grade 3/4 neuropathy (16%/0.3% compared to 8.8%/0.4%), 
hypertension (5.2%/1.0% compared to 1.4%/0.4%), bleeding 
(3.1%/0.3% compared to 0.4%/0) and vomiting (8.7%/1.4% 
compared to 2.8%/0.4%). The toxicity proﬁ  le was comparable 
to that seen in studies using a bevacizumab dose of 5 mg/kg. 
This study not only demonstrated activity of bevacizumab 
in previously treated patients, but conﬁ  rmed its activity with 
FOLFOX therapy.
The treatment of multidrug refractory disease was 
addressed in the National Cancer Institute Treatment Referral 
Centre trial, TRC-0301 (Chen et al 2006). Patients with 
progressive CRC despite treatment with the active agents 
5FU, OX, and IRI were treated with 5FU (bolus or infusion) 
in combination with bevacizumab. Disease control, deﬁ  ned 
as the combination of partial response and stable disease, 
was achieved in 33% of the subjects and PFS was found to 
be 3.5 months (95% CI of 2.0–4.3 months). The speciﬁ  ed 
primary outcome in this trial was objective RR which was 
1% in this heavily pre-treated group of patients.
Cetuximab is a monoclonal antibody inhibiting the 
EGFR. For patients with irinotecan refractory disease, 
cetuximab alone or in combination with irinotecan demon-
strated a RR of 10.8% and 22.9% (p   0.074) respectively, 
a time to treatment failure of 1.5 months and 4.1 months 
(p   0.001) respectively, but no signiﬁ  cant improvement in 
median OS (Cunningham et al 2004). A subsequent study 
added bevacizumab to both arms, combining bevacizumab 
with cetuximab alone or with cetuximab and irinotecan, for 
irinotecan refractory disease (Saltz et al 2005). This study 
was designed as a phase III study for patients that had not 
received prior anti-EGFR or anti-VEGF therapy, but suffered 
from poor accrual with the FDA approval of bevacizumab for 
ﬁ  rst-line therapy and cetuximab for refractory disease. It was 
redesigned as a randomized phase II study with the primary 
objective of evaluating the safety and efﬁ  cacy of concur-
rent administration of cetuximab and bevacizumab with or 
without irinotecan. Eighty-one subjects were enrolled; all 
had demonstrated tumor growth on an irinotecan contain-
ing regimen during any line of therapy; demonstration of 
EGFR expression was not required for enrollment. Subjects 
had received between 1 and 8 prior chemotherapy regimens 
with a median of three and most had received prior oxalipla-
tin. In this heavily pretreated population, the RR and time 
to progression (TTP) for patients receiving cetuximab and 
bevacizumab was 20% and 5.6 months respectively, and 
for those receiving irinotecan, cetuximab and bevacizumab 
was 37% and 7.9 months, respectively. As compared to the 
historical controls, the addition of bevacizumab in refractory 
disease enhanced the effects of cetuximab alone (RR 20% 
and 11%, TTP 5.6 months and 1.5 months; respectively) and 
the combination of irinotecan and cetuximab (RR 37% and 
23%, TTP 7.9 months and 4 months; respectively).
Continued bevacizumab 
in refractory disease
As of yet, there is no measurable marker to indicate resis-
tance to bevacizumab. Bevacizumab acts at the level of the 
endothelial cell, which unlike the tumor should be a geneti-
cally stable unit. Induced anti-VEGF inhibitor antibodies Biologics: Targets & Therapy 2008:2(1) 57
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have not been demonstrated. Resistance to bevacizumab 
activity may be acquired by upregulating angiogenesis 
activators or bypassing VEGF pathways. There are no 
evidence-based studies to support the use of bevacizumab 
beyond progression when used in the ﬁ  rst line of therapy. 
Extrapolation of subgroups from randomized studies, anec-
dotal reports and observational studies provide the only 
evidence of activity of bevacizumab in refractory disease 
while on a bevacizumab containing regimen (Hurwitz et al 
2006).
The BRiTE registry (Bevacizumab Regimens: Investiga-
tion of Treatment Effects and safety) was initiated in 2004 to 
evaluate the safety and efﬁ  cacy of bevacizumab in combina-
tion with chemotherapy in the ﬁ  rst line of therapy in a large, 
less-selected community based population. Using this pro-
spectively collected database, the evaluation of bevacizumab 
when used after progression on a bevacizumab containing 
regimen provides important efﬁ  cacy and safety information 
(Grothey et al 2007). Data were collected at baseline and 
every 3 months, speciﬁ  cally pertaining to changes in or dis-
continuation of therapy. Bevacizumab beyond progression 
(BBP) was deﬁ  ned as exposure to bevacizumab more than 
28 days after ﬁ  rst progression on a bevacizumab containing 
regimen. Patients who had progressed on ﬁ  rst-line therapy 
were grouped into 1) no subsequent therapy, 2) post progres-
sive therapy without bevacizumab (no BBP), or 3) post pro-
gressive therapy with bevacizumab (BBP). Of 1445 patients 
with progressive disease, 642 (44%) received BBP, 531 
(37%) received no BBP, and 253 (18%) received no treatment 
beyond ﬁ  rst progression. The OS from the time of progres-
sion was 19.2 months (95% CI of 16.8–20.7 months), 9.5 
months (95% CI of 8.4–11.2 months) and 3.6 months (95% 
CI of 2.7–4.3), in each group respectively. In a multivariate 
analysis of independent effects of patient-related factors on 
survival, the hazard ratio for the use of BBP compared to no 
BBP was 0.46 (95% CI 0.41–0.57). While there are many 
shortcomings of an observation study such as this, these 
ﬁ  ndings do support the evaluation of BBP in the prospective 
randomized phase III intergroup trial S0600/iBET (Figure 1) 
(Southwest Oncology Group. Irinotecan and cetuximab with 
or without bevacizumab in treating patients with metastatic 
colorectal cancer that progressed during ﬁ  rst-line therapy. 
(Clinical Trials.gov. URL: http://www.clinicaltrials.gov/ct/
show/NCT00499369).
Figure 1 S0600/iBET schema: irinotecan and cetuximab with or without bevacizumab in treating patients with metastatic colorectal cancer that progressed during ﬁ  rst-line therapy.
Progressive metastatic colorectal cancer 
on bevacizumab with 5FU and oxaliplatin
N = 1260
Stratification:
Zubrod performance status (0 vs. 1 or 2), 
discontinuation of oxaliplatin during first-line therapy (yes vs. no), 
planned concurrent chemotherapy (FOLFIRI vs. single-agent irinotecan), 
time from last dose of bevacizumab (14-42 days vs. ≥ 43 days). 
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Conclusion
Most patients that do not have a contraindication to receiv-
ing bevacizumab are receiving it in the ﬁ  rst line of therapy. 
Bevacizumab has been shown in randomized studies to enhance 
the effects of chemotherapy regardless of the chemotherapy 
regimen used, and in the ﬁ  rst line and second line of active 
therapy. Bevacizumab demonstrated no signiﬁ  cant activity as 
a single agent in ECOG 3200 (Giantonio et al 2007) nor when 
combined with 5FU in 5FU refractory disease in TRC-0301 
(Chen et al 2006). Bevacizumab did demonstrate activity when 
used in multiagent chemotherapy refractory disease in combi-
nation with EGFR inhibition and through subsequent lines of 
active chemotherapy regimens as in the BRiTE registry.
Appropriately powered clinical trials are needed to 
identify the role of bevacizumab through multiple lines 
of chemotherapy regimens. Study designs need to include 
1) a predetermined deﬁ  nition of ‘lines of therapy’, 2) an 
adequate sample size to allow for drop-out as subjects 
progress through lines of therapy, 3) appropriate indepen-
dent review and 4) correlative studies to identify molecular 
changes which may account for the ﬁ  ndings. Studies are 
ongoing in which bevacizumab is being evaluated during 
elective chemotherapy-free intervals for patients maintaining 
disease control, and with a second-line regimen of therapy 
for patients progressing on ﬁ  rst-line therapy. Until the 
results of these studies are known, the use bevacizumab in 
refractory disease is supported by a high level of evidence 
in bevacizumab-naïve patients, but a lower level of evidence 
in bevacizumab-treated patients.
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